AFT Pharmaceuticals Limited Stock

Equities

AFT

NZAFTE0001S4

Pharmaceuticals

End-of-day quote New Zealand S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
2.8 NZD -3.45% Intraday chart for AFT Pharmaceuticals Limited -6.67% -20.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 193M 116M Sales 2025 * 220M 133M Capitalization 294M 177M
Net income 2024 * 15M 9.03M Net income 2025 * 17M 10.23M EV / Sales 2024 * 1.67 x
Net Debt 2024 * 28.28M 17.02M Net Debt 2025 * 26.88M 16.18M EV / Sales 2025 * 1.46 x
P/E ratio 2024 *
19.3 x
P/E ratio 2025 *
16.9 x
Employees 100
Yield 2024 *
0.58%
Yield 2025 *
0.81%
Free-Float 25.53%
More Fundamentals * Assessed data
Dynamic Chart
AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV MT
New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment MT
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment MT
AFT Pharmaceuticals Limited, Massey Ventures, Gilles Mcindoe Research Institute to Develop Scar Treatment CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals MT
Aft Expands Its Co-Operation with Hikma Pharmaceuticals CI
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024 MT
AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024 CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4% MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US MT
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus CI
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate MT
More news
1 day-3.45%
1 week-6.67%
Current month-6.67%
1 month-11.11%
3 months-25.53%
6 months-15.92%
Current year-20.00%
More quotes
1 week
2.80
Extreme 2.8
3.00
1 month
2.80
Extreme 2.8
3.24
Current year
2.80
Extreme 2.8
3.85
1 year
2.80
Extreme 2.8
3.92
3 years
2.80
Extreme 2.8
5.00
5 years
2.54
Extreme 2.54
5.65
10 years
1.70
Extreme 1.7
5.65
More quotes
Managers TitleAgeSince
Founder - 97-09-03
Founder - 97-09-03
Director of Finance/CFO - 97-09-03
Members of the board TitleAgeSince
Director/Board Member 67 20-12-22
Chairman - 15-06-21
Founder - 97-09-03
More insiders
Date Price Change Volume
24-05-10 2.8 -3.45% 10,676
24-05-09 2.9 -1.02% 16,372
24-05-08 2.93 +1.03% 103,317
24-05-07 2.9 -2.36% 32,435
24-05-06 2.97 -1.00% 13,505

End-of-day quote New Zealand S.E., May 09, 2024

More quotes
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.8 NZD
Average target price
3.7 NZD
Spread / Average Target
+32.14%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW